Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lanthanum Carbonate · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | 750-2250mg/day, tid (three times a day), 8 weeks |
| Arm 2 | ACTIVE_COMPARATOR | 1500-4500mg/day, tid, 8 weeks |
| Name | Type | Description |
|---|---|---|
| Lanthanum carbonate (BAY77-1931) | DRUG | - |
| Calcium carbonate | DRUG | - |
Inclusion Criteria: * Pre-dialysis serum phosphate levels: ≧5.6 mg/dL and \<11.0 mg/dL at 1 week after the initiation of the washout period. * Out-patient * Undergoing hemodialysis three times per week for at least previous 3 consecutive months Exclusion Criteria: * Pre-dialysis serum phosphate l...
Lanthanum Carbonate is used for hyperphosphatemia, a condition of elevated phosphate levels in the blood. It is being developed as a small molecule treatment for patients with this condition, including those on dialysis. The drug is currently in Phase 3 clinical development.
Lanthanum Carbonate is being developed by Bayer AG, a pharmaceutical company. Bayer's ticker symbol is BAYRY. The drug is currently in Phase 3 clinical trials for the treatment of hyperphosphatemia.
Lanthanum Carbonate is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Three clinical trials have been completed, with a total enrollment of 316 patients.
Lanthanum Carbonate has completed three clinical trials: NCT00767637, a Phase 2 study measuring lanthanum concentrations in bone; NCT01514851, a Phase 3 double-blind comparative study with calcium carbonate; and NCT01518387, an open study in peritoneal dialysis patients. All trials were conducted in Japan.
Yes, Lanthanum Carbonate is also known as BAY77-1931. Clinical trials for the drug use this alternative name, such as NCT01514851, which is titled 'Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate'.